Durability is recognized as the Achilles' heel of endovascular interventions in the infrapopliteal arteries. It was therefore pleasing to see in this issue of the JEVT a study of a novel device that can provide 3-year primary patency greater than 80% and freedom from clinically driven target lesion revascularization over 87%. 1 While it is true that these results apply to a selected group of patients with focal tibial artery disease that may not represent occlusive disease patterns more commonly encountered in critical limb ischemia (CLI), they also represent a compelling proof of concept suggesting bioresorbable polymer technology has a role in the treatment of these most challenging tibial artery lesions.
However, before the ink has even dried on the manuscript the Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular, Santa Clara, CA, USA) had been withdrawn from the market, ending a promising phase in research and development for BVS in the periphery. That withdrawal has been closely linked to concerning clinical trial findings in coronary artery disease, which resulted in "low commercial sales," according to the manufacturer. We believe this is an ideal opportunity to discuss factors that influence devices used in both coronary and peripheral circulations to answer the question of why devices with great promise may be withdrawn from production due to considerations other than patient benefit.
So . . . What Happened in the Coronary Arteries?
The Absorb BVS came into use in the coronary arteries with several potential benefits, including no permanent metallic implant, restoration of vasomotion, the opportunity for positive vessel remodeling, simplified restenosis treatment, no hindrance to future bypass surgery, and reduction of late scaffold thrombosis. However, most of these benefits were unproven and considered less than certain at the start of the clinical trials. Moreover, if they were to come to fruition, these benefits would not be immediately apparent but materialize only months to years after the treatment. Perhaps of most importance, the clinical results of BVS would need to be proven noninferior to the very high bar set by contemporary coronary drug-eluting stent (DES) platforms.
While potentially unavoidable from a regulatory standpoint, comparison of this first-generation bioresorbable scaffold head-to-head against a seventh-generation metal DES was unfortunate. 2 While few would doubt that Absorb BVS outcomes could compare well with angioplasty alone or early-generation coronary DES, the current state of percutaneous coronary interventions is marked by low, single-digit target lesion revascularization and stent thrombosis rates due to the properties of current DES devices. 2 In this context, the likelihood that a first-generation BVS could rival or surpass the performance of a seventh-generation device accompanied by mature coronary treatment protocols was predictably low. That the BVS fell only marginally short against such odds 799735J ETXXX10.1177/1526602818799735Journal of Endovascular TherapyDeRubertis et al editorial2018 suggests that future iterations of BVS have significant potential to make a meaningful contribution to the armamentarium of devices available for the treatment of coronary disease.
A further contributor to the demise of Absorb was the limited commercial appetite for a slow-and-steady approach to rolling out this new technology. Significant capital investment was made in research and development, which brought pressure to bear from investors to fast track commercial returns. This resulted in an early Conformité Européenne mark, with mainstream European adoption before the market had learned the lessons that would optimize implantation technique, lesion selection, and patient outcomes. By the time the importance of fastidious deployment technique was understood, [3] [4] [5] many of the patients who would ultimately experience target lesion failure had already been enrolled in the pivotal trials. [6] [7] [8] [9] At that point the die had been cast and the fate of the device became inevitable. A final point worth considering is that the reliance on such fastidious pre-and postdilation and intravascular imaging for sizing may have been a barrier to generalized uptake of the device in a landscape where the comparatively simple deployment of DES made maintaining the status quo an easier option. Ultimately, operators found it difficult to justify BVS use for hypothetical benefits in the face of a more technically demanding implantation procedure and a heightened risk of very late scaffold thrombosis.
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How Could the Device Have Been Improved?
Like any early-generation device, the Absorb BVS was imperfect. The rectangular, thick, and wide strut geometry, bulky crossing profile, and 0.5-mm limit to postdilation are likely to have exacerbated the scaffold underexpansion and malapposition seen in patients who did not undergo careful pre-and postdilation during implantation. 11 Malapposition triggers significant hemodynamic alterations, leaving the underexpanded segments prone to flow separation, recirculation, and low wall shear stress, which is known to lead to platelet aggregation, fibrin deposition, and higher rates of thrombogenicity. 12 Thick struts are, in fact, associated with both restenosis and thrombosis. 13, 14 Furthermore, the Absorb polymer underwent very slow degradation (up to 36 months), which is thought to be excessive and poses an issue with regard to length of dual antiplatelet therapy usage. 10 The next generation of bioresorbable scaffolds have already achieved thinner struts, faster resorption rates, lower crossing profiles, and can be postdilated significantly beyond the nominal diameter.
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Is There a Different Treatment Paradigm in Peripheral Arteries Compared to the Coronary Arteries?
Coronary and peripheral arteries are similar in size but differ in almost every other way, most notably flow characteristics, vessel wall structure, degree of vasomotion, and the composition of atherosclerotic plaque. 16, 17 In the coronary circulation, the allure of a scaffold that biologically dissolves once its mechanical properties are no longer needed includes the reduction in late scaffold thrombosis, which accounts for adverse patient outcomes at a rate of 2% per year following coronary intervention. 18, 19 Most concerning of these outcomes is target vessel myocardial infarction, which can occur acutely with scaffold thrombosis and is potentially fatal. Current-generation DES have effectively reduced the risk of late scaffold thrombosis, with rates <1% at 1 year (and 0.2% to 0.4% per year thereafter). 2, 20 They are also very effective at maintaining patency, with 1-year in-stent restenosis rates as low as 5%. 2 Treatment indications and therapeutic goals are quite different in the peripheral circulation and specifically the infrapopliteal circulation, where BVS have been applied. Revascularization for below-the-knee (BTK) disease is almost universally performed for CLI, where areas of tissue loss require revascularization to avoid gangrene, infection, and amputation. Once the wounds have healed, target lesion failure is unlikely to have a detrimental effect, even in the event of a late scaffold thrombosis, which was a rare but significant adverse event observed in the coronary ABSORB trials. 2, 15 Had the BVS been implanted in the infrapopliteal arteries, these very late thromboses would have occurred long after wound healing was complete.
Among the most important factors to consider when evaluating the use of a novel technology are the alternative treatment modalities and the established standard of care. It is in this realm that BVS shows such promise in the peripheral circulation, as there is a stark unmet need compared to the well-established treatment paradigm and excellent outcomes for coronary interventions. 21 Currently in the United States, the only on-label treatments for tibial disease are atherectomy, which has little supportive published data, and angioplasty alone. For BTK arterial disease these endovascular strategies achieve 1-year restenosis rates of at least 30% to 50%, which offer significant room for improvement. 21 While implantation of permanent scaffolds could offer better results, there has been a recent dramatic shift away from permanent implants for the superficial femoral artery, and most interventional specialists are less inclined to place permanent implants in the tibial circulation where a native, implant-free vessel may be the last bypass option for a threatened limb.
What About the Commercial Market?
The commercial market for the treatment of peripheral artery disease (PAD) is similar to that for coronary intervention; however, unlike PAD the coronary market is contracting. 22, 23 In contrast, there are still many CLI patients who go untreated and may benefit from revascularization. Despite an increasing awareness of the importance of establishing inline blood flow to the site of foot ulceration, there remains a significant proportion of patients who undergo lower extremity amputation without any form of revascularization. 24 This indicates a significant growth opportunity for BTK devices, especially as PAD awareness is paired with increased availability of vascular providers. Moreover, as our population ages and lifestyle-related diseases such as obesity and type II diabetes become more prevalent, we will see a rising incidence of lower limb arterial disease and CLI. While the discontinuation of the Absorb BVS was a commercial decision based on coronary sales, the manufacturer may have overlooked this large potential in the peripheral market and missed a significant opportunity.
It is time that medical device development for the treatment of PAD be extricated from the research and development programs of the coronary arteries. Both markets are equally large. One is contracting, the other expanding, and the needs of the two could not be more disparate. It is our view that with the discontinuation of the Absorb BVS a massive opportunity has been disregarded, one that may have brought a new era of patency for interventions below the knee and with it a host of improved outcomes for our patients.
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